Statin adherence and the risk of major coronary events in patients with diabetes: A nested case-control study

British Journal of Clinical Pharmacology

Volumn 71, Issue 5, 2011, Pages 766-776

  Ruokoniemi, Päivi ^a,b   Korhonen, Maarit J ^a,c   Helin Salmivaara, Arja ^a,d   Lavikainen, Piia ^c   Jula, Antti ^e   Junnila, Seppo Y T ^f   Kettunen, Raimo ^g   Huupponen, Risto ^a,h  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f Salo Health Center   (Finland)

^g PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adherence to medical regimen; Diabetes mellitus; Myocardial infarction; Myocardial revascularization; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FINLAND; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AGED; CARDIOVASCULAR AGENTS; CASE-CONTROL STUDIES; CORONARY DISEASE; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FINLAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION;

EID: 79953853323     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03895.x     Document Type: Article

References (56)

1. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009; 32 (Suppl. 1): S13-S61.
2. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26 (Suppl. 1): S83-S86.
3. Jones P, Davidson M, Stein E, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-60.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial investigators. N Engl J Med 1996; 335: 1001-9.
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
8. Heart protection Study Collaborative Group. MRC/BHF heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
9. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
10. Schramm T, Gislason G, Køber L, Rasmussen S, Rasmussen J, Abildstrøm S, Hansen M, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117: 1945-54.
11. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Östergren J, Tuomilehto J, Thrainsdottir I. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
12. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-25.
13. Costa J, Borges M, David C, Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006; 332: 1115-24.
14. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
15. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29: 1478-85.
16. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RMC. Long term persistence with statin treatment in daily medical practice. Heart 2004; 90: 1065-6.
17. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005; 59: 564-73.
18. Benner J, Glynn R, Mogun H, Neumann P, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.
19. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458-62.
20. Donnelly LA, Doney ASF, Morris AD, Palmer CNA, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med 2008; 25: 850-5.
21. Furu K, Wettermark B, Andersen M, Martikainen J, Almarsdottir A, Sørensen H. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010; 106: 86-94.
22. The National Agency for Medicines (ed.). Classification of Medicines and the Defined Daily Doses 2007. Helsinki: National Agencies for Medicines, 2007.
23. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari P, Mähönen M, Niemelä M, Kuulasmaa K, Palomäki P, Mustonen J, Lehtonen A, Arstila M, Vuorenmaa T, Lehto S, Miettinen H, Torppa J, Tuomilehto J, Kesäniemi YA, Pyörälä K, Salomaa V. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 132-7.
24. Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol 2008; 168: 329-35.
25. Korhonen M, Huupponen R, Ruokoniemi P, Helin-Salmivaara A. Protopathic bias in observational studies on statin effectiveness. Eur J Clin Pharmacol 2009; 65: 1167-8.
26. Tamim H, Monfared AAT, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007; 16: 250-8.
27. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 2006; 28: 1411-24, Discussion 1410.
28. Andrade S, Kahler K, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-74.
29. Schneeweiss S, Patrick A, Maclure M, Dormuth C, Glynn R. Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. Am J Manag Care 2007; 13: 445-52.
30. Perreault S, Dragomir A, Blais L, Brard A, Lalonde L, White M, Pilon D. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009; 65: 1013-24.
31. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-30.
32. Altman D, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003; 326: 219.
33. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
34. Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Fuller JH, CARDS Investigators. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002; 19: 201-11.
35. Sacks FM, Pfeffer MA, Moye L, Brown L, Rouleau JL, Hartley LH, Rouleau J, Grimm R, Sestier F, Wickemeyer W, Cole TG, Braunwald E, The Care Investigators. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991; 68: 1436-46.
36. Helin-Salmivaara A, Lavikainen P, Ruokoniemi P, Korhonen M, Huupponen R. Persistence with statin therapy in diabetic and non-diabetic persons: a nation-wide register study in 1995-2005 in Finland. Diabetes Res Clin Pract 2009; 84: e9-e11.
37. Bouchard M, Dragomir A, Blais L, Bérard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007; 63: 698-708.
38. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann A. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009; 169: 260-8.
39. McGinnis BD, Olson KL, Delate TMA, Stolcpart RS. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Manag Care 2009; 15: 689-95.
40. Zhang Q, Safford M, Miller D, Crystal S, Rajan M, Tseng C, Pogach L. Short-term statin exposure is associated with reduced all-cause mortality in persons with diabetes. Med Care 2007; 45: 308-14.
41. Ho PM, Magid D, Masoudi F, McClure D, Rumsfeld J. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 2006; 6. Available at: (last accessed 1 December 2009).
42. Ho PM, Rumsfeld J, Masoudi F, McClure D, Plomondon M, Steiner J, Magid D. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836-41.
43. Simpson S, Eurich D, Majumdar S, Padwal R, Tsuyuki R, Varney J, Johnson J. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
44. Brookhart MA, Patrick A, Dormuth C, Avorn J, Shrank W, Cadarette S, Solomon D. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166: 348-54.
45. Dormuth C, Patrick A, Shrank W, Wright J, Glynn R, Sutherland J, Brookhart MA. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009; 119: 2051-7.
46. Aromaa A, Koskinen S. Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Publications of the National Public Health Institute B3/2002. Helsinki: National Public Health Institute, 2002 (accessed 1 May 2009).
47. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303.
48. Pencina M, D'Agostino R, Larson M, Massaro J, Vasan R. Predicting the 30-year risk of cardiovascular disease: the Framingham heart study. Circulation 2009; 119: 3078-84.
49. Schisterman E, Cole S, Platt R. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009; 20: 488-95.
50. Cubbon R, Gale C, Rajwani A, Abbas A, Morell C, Das R, Barth JH, Grant PJ, Kearney MT, Hall AS. Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care 2008; 31: 363-5.
51. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Rosenson RS, Williams CD, Wilson PW, Kirkman MS, American Diabetes Association, American Heart Association, American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol 2010; 55: 2878-86.
52. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-72.
53. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394-403.
54. Dormuth C, Schneeweiss S, Brookhart A, Bassett K, Wright J. Factors related to splitting tablets of HMG-CoA reductase inhibitors: a population-based analysis in British Columbia. Pharmacoepidemiol Drug Saf 2007; 16: S137.
55. Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol 2009; 104: 1241-8.
56. Filion K, Schneider-Lindner V, Karp I, Lvesque L, Brophy J, Suissa S. Continuation of statin treatment and mortality: a note of caution on excessive benefits. Arch Intern Med 2009; 169: 1080.